RBM7

Across TCGA pan-cancer cohorts, RBM7 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RBM7 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RBM7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBM7 expression acts as an unfavorable survival marker.

OV and LIHC are the cancer types where RBM7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.279	0.541	.040	18	view →
LIHC	OS	Median	All	0.188	0.669	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RBM7–OV (DFS)

Open the OV breakdown →